Endonovo Therapeutics annual shares outstanding
2011
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
Endonovo Therapeutics Shares Outstanding History (ENDV)
Endonovo Therapeutics reported 213.2M shares outstanding at the end of fiscal 2022.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | 213.2M | 138.7M | +186.22% |
| 2021 | 2021-12-31 | 74.5M | 50.0M | +203.62% |
| 2020 | 2020-12-31 | 24.5M | 23.3M | +1963.29% |
| 2019 | 2019-12-31 | 1.2M | 758,141 | +175.88% |
| 2018 | 2018-12-31 | 431,063 | −316.5M | −99.86% |
| 2017 | 2017-12-31 | 317.0M | 182.6M | +135.94% |
| 2016 | 2016-12-31 | 134.3M | 26.3M | +24.36% |
| 2015 | 2016-03-24 | 108.0M | 26.6M | +32.67% |
| 2014 | 2014-12-31 | 81.4M | 27.7M | +51.65% |
| 2012 | 2012-12-31 | 53.7M | 15.4M | +40.14% |
| 2011 | 2011-12-31 | 38.3M | — | — |
Endonovo Therapeutics quarterly shares outstanding
Q4.11
Q4.12
Q1.13
Q2.13
Q3.13
Q4.14
Q1.15
As of Aug 19, 2015
Q3.15
As of Nov 16, 2015
Q3.15
Q4.15
Q4.15
Q1.16
Q1.16
Q2.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q3 2023 | 2023-09-30 | 318.8M | 159.5M | +100.19% |
| Q2 2023 | 2023-06-30 | 278.8M | 128.4M | +85.34% |
| Q1 2023 | 2023-03-31 | 270.3M | 189.0M | +232.34% |
| Q4 2022 | 2022-12-31 | 213.2M | 138.7M | +186.22% |
| Q3 2022 | 2022-09-30 | 159.2M | 90.0M | +130.12% |
| Q2 2022 | 2022-06-30 | 150.4M | 89.8M | +147.99% |
| Q1 2022 | 2022-03-31 | 81.3M | 29.8M | +57.85% |
| Q4 2021 | 2021-12-31 | 74.5M | 50.0M | +203.62% |
| Q3 2021 | 2021-09-30 | 69.2M | 51.9M | +299.87% |
| Q2 2021 | 2021-06-30 | 60.7M | 53.4M | +740.90% |
| Q1 2021 | 2021-03-31 | 51.5M | 44.3M | +614.25% |
| Q4 2020 | 2020-12-31 | 24.5M | 23.3M | +1963.29% |
| Q3 2020 | 2020-09-30 | 17.3M | −817.0M | −97.93% |
| Q2 2020 | 2020-06-30 | 7.2M | −723.3M | −99.01% |
| Q1 2020 | 2020-03-31 | 7.2M | −509.6M | −98.60% |
| Q4 2019 | 2019-12-31 | 1.2M | −429.9M | −99.72% |
| Q3 2019 | 2019-09-30 | 834.3M | 452.9M | +118.76% |
| Q2 2019 | 2019-06-30 | 730.6M | 374.3M | +105.06% |
| Q1 2019 | 2019-03-31 | 516.8M | 178.8M | +52.91% |
| Q4 2018 | 2018-12-31 | 431.1M | 114.1M | +36.00% |
| Q3 2018 | 2018-09-30 | 381.4M | 97.3M | +34.26% |
| Q2 2018 | 2018-06-30 | 356.3M | 112.1M | +45.91% |
| Q1 2018 | 2018-03-31 | 338.0M | 112.3M | +49.75% |
| Q4 2017 | 2017-12-31 | 317.0M | 182.6M | +135.94% |
| Q3 2017 | 2017-09-30 | 284.1M | 159.3M | +127.68% |
| Q2 2017 | 2017-06-30 | 244.2M | 126.3M | +107.10% |
| Q1 2017 | 2017-03-31 | 225.7M | 116.1M | +105.88% |
| Q4 2016 | 2016-12-31 | 134.3M | 26.0M | +24.05% |
| Q2 2016 | 2016-09-30 | 124.8M | 16.7M | +15.50% |
| Q1 2016 · Jun 30 | 2016-06-30 | 117.9M | 13.1M | +12.50% |
| Q1 2016 · May 27 | 2016-05-27 | 109.6M | 6.3M | +6.12% |
| Q4 2015 | 2016-03-31 | 108.3M | 6.3M | +6.21% |
| Q4 2015 | 2016-03-24 | 108.0M | 6.7M | +6.65% |
| Q3 2015 · Dec 31 | 2015-12-31 | 104.8M | 8.4M | +8.68% |
| As of Nov 16, 2015 | 2015-11-16 | 103.3M | 21.9M | +26.86% |
| Q3 2015 · Sep 30 | 2015-09-30 | 102.0M | 26.1M | +34.45% |
| As of Aug 19, 2015 | 2015-08-19 | 101.3M | 40.1M | +65.63% |
| Q1 2015 | 2015-03-31 | 96.4M | 35.3M | +57.69% |
| Q4 2014 | 2014-12-31 | 81.4M | 27.7M | +51.65% |
| Q3 2013 | 2013-09-30 | 75.8M | 37.5M | +97.92% |
| Q2 2013 | 2013-06-30 | 61.2M | — | — |
| Q1 2013 | 2013-03-31 | 61.2M | — | — |
| Q4 2012 | 2012-12-31 | 53.7M | — | — |
| Q4 2011 | 2011-12-31 | 38.3M | — | — |
Endonovo Therapeutics shares outstanding trends
Over the last five reported fiscal years, Endonovo Therapeutics's shares outstanding moved from 317.0M to 213.2M, a change of −103.7M. The latest reported quarter, Q3 2023, shows 318.8M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics filings at SEC.gov ↗